Multiple myeloma

Cytokine stimulation can increase the potency and durability of engineered T cells

TurboCAR™ is designed to recapitulate cytokine signaling selectively in CAR T cells and may have potential benefits, subject to investigation

• Minimizes systemic toxicity
• Does not stimulate host immune cells which could reject CAR
• Delivers survival benefit selectively to CAR T cells

Opportunities for development

• Improving the efficacy of CAR T cells
• Reducing CAR T cell dose requirement
• Overcoming exhaustion to enable CAR T therapies to be used for solid tumors